# Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site

> **NCT00148135** · PHASE2 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center**

## Conditions studied

- Carcinoma of Unknown Primary

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00148135
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-05
- **Primary completion:** 2006-04
- **Final completion:** 2007-10
- **Target enrollment:** — (—)
- **Why stopped:** recruitment goals met
- **Last updated:** 2008-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00148135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00148135, "Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00148135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*